🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Un tratamiento libre de quimioterapia presenta resultados prometedores en pacientes con cáncer de mama metastático HER2 positivo con receptores hormonales positivos (HER2+/ER+) Santiago Escrivá presenta hoy los primeros resultados en SABCS ➡️ linke.to/SABCS23VHIO

Grateful for an extraordinary year collaborating with the Cancer Genetics and Breast Cancer groups. Your unwavering dedication and passion are a daily inspiration #TeamWork 🤝 #CancerResearch 🧬 #Gratitude 😊

🎁 Merry Christmas from Vall d’Hebron Institute of Oncology (VHIO)

Germline Testing in Patients With Breast Cancer: ASCO–Society of Surgical Oncology Guideline 🔹️ BRCA1/2 testing recommended for newly diagnosed breast cancer patients aged ≤65 and select cases >65 🔹️ Recurrent breast cancer patients eligible for PARP inhibitor therapy

Es urgente poner en marcha acciones para lograr la igualdad efectiva entre hombres y mujeres en las carreras científicas, tanto en el acceso a estas disciplinas como en el desarrollo profesional, sobre todo en puestos de liderazgo. Algunas científicas de Vall d’Hebron Institute of Oncology (VHIO) nos dan su visión

🧬 Analizar la deficiencia en la reparación del ADN de los tumores de mama y ovario con variantes patogénicas germinales en los genes RAD51C o RAD51D podría ser útil para guiar el tratamiento dirigido 🗞️ Publicado en JAMA Network Open ➡️ linke.to/ADNRAD51CASTVH…

Very helpful discussion by Cristina Saura on how to think about adjuvant therapies in pts with gBRCAm Could we consider sequential adjuvant abemaciclib after olaparib in high-risk pts with ER+ BC and gBRCAm? OncoAlert #bcsm #ESMOBreast24

#ESMOBreast24: Assisted ART does not negatively affect maternal prognosis or pregnancy outcomes for young women w/ a history of #BreastCancer and #BRCA mutations, according to the first analysis of a global study. #ESMODailyReporter 👉dailyreporter.esmo.org/esmo-breast-ca…

Excited to present at #ESMOBreast24 the results of the PRISMA study, which evaluates the addition of PRS in breast cancer risk estimation for ATM, CHEK2, and PALB2 carriers! #breastcancer #research

Day off ☀️

🎉 Felicidades compañeros!🎉Diego Gomez-Puerto SHARELA VEGA Gaspar Molina Lores ✔️ FIN a una super residencia en #oncologiamedica Vall d'Hebron Vall d’Hebron Institute of Oncology (VHIO) Merecida celebración 👏🏼 Gracias por el #VHIOaward 💪🏼 #influencer 🤜🏼 Felicidades al adjunto revelación Dr. Garré Este año más y mejor☺️

T-DXd is approved for patients with any HER2+ solid tumor (IHC 3+ on tissue) Could ctDNA also allow to identify pts benefiting from T-DXd? In the HERALD trial, 62 pts with 16 cancer types having ctDNA-detected HER2 amplifications received T-DXd ORR 56% ascopubs.org/doi/10.1200/JC…

Half of people with inherited BRCA1/2 mutations are men, yet very few men are offered genetic testing or know the importance to their own health. Article reviews data & screening recommendations aimed to help men take action to reduce their risk of cancer. ja.ma/3WG4Nds

🔬 El Grupo de Cáncer de Mama del VHIO se especializa en la investigación clínica enfocada en el desarrollo de fármacos y la investigación traslacional asociada. 👩‍🔬 Descubre quiénes son 👉linke.to/CancerMamaVHIO #ClínicaVHIO

Two weeks to #ESMO24. Multiple important breast onc trials readouts across disease subtypes, including OS from KN522, DB12, 4y of NATALEE, CAPItello290, phase 1 studies of novel ADCs, IO, targeted drugs, and so much more. The countdown is on. See you soon in Barcelona! 🇪🇸 #bcsm

The unmissable Schlam Pocket Algorithms are back! Terrific resource 👇

#SEOM24 💥 Congrats to a brilliant presentation by Alejandra Rezqallah ✔️ Polygenic risk score (PRS) + #BOADICEA optimizes the risk for preventive #ET ✔️ #ATM #CHEK2 #noncarriers risk is modified by #PRS 👏🏽 Congrats to the Vall d’Hebron Institute of Oncology (VHIO) team judith balmaña Adrià López 🐘 Mara SEOM

Después de 5 años de virtualidad (10/03/2020 - 03/03/2025), volvemos: 👀no te vimos Oriol Mirallas MD

👏 Celebrating the strong contribution of our researchers from #VHIO’s Hereditary Cancer Genetics Group, led by judith balmaña, at #BRCA2025 in Montreal. 🎯 Advancing prevention and treatment in hereditary cancer through science and dedication.

The curves everybody’s been waiting for. First line T-DXd + pertuzumab significantly prolonged PFS over THP for HER2+ MBC (40.7 vs 26.9 months, HR 0.56, p<0.001), doubled the rate of complete responses (15% vs 8%) and had a positive OS trend (HR 0.84). Practice changing data.